Jiangxi Xinganjiang Pharmaceutical Co (BJSE:920367) Research & Development: ¥19.5 Mil (TTM As of Mar. 2026)


BJSE:920367 Jiangxi Xinganjiang Pharmaceutical Co Ltd BJSE:920367
60 GF Score
Price ¥21.80
GF Value ¥12.14
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Jiangxi Xinganjiang Pharmaceutical Co Research & Development?

Jiangxi Xinganjiang Pharmaceutical Co BJSE:920367 60 Research & Development is ¥19.5 Mil as of Mar. 2026. GuruFocus rates BJSE:920367 with a GF Score™ of 60/100 and a GF Value™ of ¥12.14 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Jiangxi Xinganjiang Pharmaceutical Co's Research & Development for the three months ended in Mar. 2026 was ¥5.2 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was ¥19.5 Mil.

Jiangxi Xinganjiang Pharmaceutical Co  (BJSE:920367) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Jiangxi Xinganjiang Pharmaceutical Co Research & Development Related Terms

Jiangxi Xinganjiang Pharmaceutical Co Research & Development Historical Data

* Premium members only.

The historical data trend for Jiangxi Xinganjiang Pharmaceutical Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jiangxi Xinganjiang Pharmaceutical Co Research & Development Chart

Jiangxi Xinganjiang Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.21 8.86 10.03 8.80 15.97

Jiangxi Xinganjiang Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.74 4.25 4.57 5.41 5.23
BJSE:920367
60GF Score
Jiangxi Xinganjiang Pharmaceutical Co Ltd BJSE:920367
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jiangxi Xinganjiang Pharmaceutical Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥19.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ¥19.5 Mil mean?
Jiangxi Xinganjiang Pharmaceutical Co (BJSE:920367) has a Research & Development of ¥19.5 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Jiangxi Xinganjiang Pharmaceutical Co and its competitors.
Is Jiangxi Xinganjiang Pharmaceutical Co's Research & Development too high?
Jiangxi Xinganjiang Pharmaceutical Co's current Research & Development is ¥19.5 Mil. Overall, Jiangxi Xinganjiang Pharmaceutical Co has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jiangxi Xinganjiang Pharmaceutical Co's Research & Development compare to ZTS and UTHR?
Jiangxi Xinganjiang Pharmaceutical Co's Research & Development of ¥19.5 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Jiangxi Xinganjiang Pharmaceutical Co and its competitors. Jiangxi Xinganjiang Pharmaceutical Co's current Research & Development is ¥19.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangxi Xinganjiang Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Jiangxi Xinganjiang Pharmaceutical Co (BJSE:920367) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥12.14, compared to a current price of ¥21.80 — trading 79.6% above its estimated fair value. The current Research & Development is ¥19.5 Mil. Jiangxi Xinganjiang Pharmaceutical Co's overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Jiangxi Xinganjiang Pharmaceutical Co (BJSE:920367), the current Research & Development is ¥19.5 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Jiangxi Xinganjiang Pharmaceutical Co (BJSE:920367) Overvalued in 2026?

Based on GuruFocus' analysis, Jiangxi Xinganjiang Pharmaceutical Co stock appears to be overvalued. The current stock price of ¥21.80 is trading 79.6% above its estimated GF Value™ of ¥12.14. GuruFocus considers Jiangxi Xinganjiang Pharmaceutical Co to be Significantly Overvalued.

Key valuation signals for BJSE:920367:

  • Research & Development: ¥19.5 Mil
  • GF Value™: ¥12.14 vs. price of ¥21.80 (79.6% above fair value)
  • GF Score™: 60/100 with 4 warning signs

No single metric tells the full story. See the BJSE:920367 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Jiangxi Xinganjiang Pharmaceutical Co Business Description

Address No. 36 Yunzhang Road, Industrial Park, Jizhou District, Jiangxi Province, Ji'an City, CHN, 343000
Jiangxi Xinganjiang Pharmaceutical Co Ltd conducts research and development, production, and sales of chemical raw materials, chemical preparations, and Chinese patent medicines. The company's raw material medicine products are mainly calcium gluconate, zinc gluconate, ferrous gluconate, and other gluconate series raw material medicines. Its main chemical preparations are vitamin C chewable tablets and compound Yinqiao aminomin capsules, and Phenaminokamin Tablets.
60GF Score

Get the complete analysis for BJSE:920367

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥21.80
Price
¥12.14
GF Value